RxDoctor Payments Data

Theresa Rogers

Nurse Practitioner · Sterling, ILNPI 1770055881

Payments from drug & device makers

$1,839in general payments, 2019–2025

Across 75 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$282
  • Boehringer Ingelheim$227
  • Merck$183
  • AstraZeneca$178
  • Boston Scientific$177
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$134
  • plus $658 from 9 others

What the payments were for

  • Food & beverage$1,839100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,839 in reported general payments places this provider in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$76,067
Medicare patients
292
Services billed
1,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban297$321,147
EntrestoSacubitril/Valsartan128$134,933
Repatha SureclickEvolocumab77$122,149
Praluent PenAlirocumab39$52,158
XareltoRivaroxaban42$44,835
BrilintaTicagrelor28$21,356
Ezetimibe187$4,726
Metoprolol Succinate458$4,620
Atorvastatin Calcium411$4,004
Rosuvastatin Calcium282$3,402
ClopidogrelClopidogrel Bisulfate268$2,594
Carvedilol299$2,435
Furosemide336$1,607
Nebivolol Hcl14$1,562
Lisinopril218$1,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$321,147297 claims
NovartisEntresto$282$134,933128 claims
Johnson & JohnsonXarelto$96$44,83542 claims
AstraZenecaBrilinta$178$21,35628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Sterling

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →